Liquid Biopsy

Hossein Borghaei, DO, MS, spoke with Healio about his important takeaways from the International Lung Cancer Congress.

The FDA approved FoundationOne Liquid CDx to be used as a companion diagnostic to identify MET exon 14 skipping in patients with metastatic non-small cell lung cancer, according to a company-issued press release.

An electronic, odor-based tool accurately distinguished pancreatic and ovarian cancer specimens from benign disease and control specimens by analyzing vapors emanating from blood samples, according to results of a small, preliminary study.

Liquid biopsy-driven rechallenge with panitumumab led to objective responses in about one-third of patients with metastatic colorectal cancer, according to results of the phase 2 CHRONOS study presented at the virtual ASCO Annual Meeting.

A novel risk-stratification model developed for noninvasive identification of T1 colorectal cancer may help avoid unnecessary surgeries for high-risk patients.

Plasma cell-free DNA integrity assessed prior to surgery accurately predicted achievement of pathologic complete response to neoadjuvant chemotherapy among patients with locally advanced breast cancer, according to study results.

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, spoke with Healio about presentations from the Chemotherapy Foundation Symposium exploring liquid biopsy in lung cancer.

In this video, Charu Aggarwal, MD, MPH, Leslye M. Heisler assistant professor for lung cancer excellence at the University of Pennsylvania Abramson Cancer Center, discusses the role of liquid biopsies for the management of non-small cell lung cancer.

The FDA has approved a new pan-tumor liquid biopsy test that can help guide treatment decisions for patients with solid tumors. It was the top story in hematology/oncology last week.

The FDA approved FoundationOne Liquid CDx, a comprehensive pan-tumor liquid biopsy test.